232 related articles for article (PubMed ID: 30523119)
1. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study.
Castillo JJ; Itchaki G; Paludo J; Varettoni M; Buske C; Eyre TA; Chavez JC; Shain KH; Issa S; Palomba ML; Pasvolsky O; Simpson D; Talaulikar D; Tam CS; Tedeschi A; Ansell SM; Nayak L; Treon SP
Blood; 2019 Jan; 133(4):299-305. PubMed ID: 30523119
[TBL] [Abstract][Full Text] [Related]
2. How we manage Bing-Neel syndrome.
Castillo JJ; Treon SP
Br J Haematol; 2019 Nov; 187(3):277-285. PubMed ID: 31430829
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib for the treatment of Bing-Neel syndrome, a complication of Waldenström macroglobulinemia: Patient case report.
Hartsell L; Janes A; Larck C; Park S; Arnall JR
J Oncol Pharm Pract; 2019 Sep; 25(6):1534-1539. PubMed ID: 30760164
[TBL] [Abstract][Full Text] [Related]
4. Bing-Neel Syndrome Successfully Treated with Tirabrutinib.
Oyama T; Taoka K; Chiba A; Matsuda K; Maki H; Masamoto Y; Kurokawa M
Intern Med; 2022 Dec; 61(23):3575-3579. PubMed ID: 35569989
[TBL] [Abstract][Full Text] [Related]
5. Bing-Neel syndrome: A case reports.
Demircioğlu S; Oltulu P; Emlik GD; Tekinalp A; Çeneli Ö
J Oncol Pharm Pract; 2021 Oct; 27(7):1758-1761. PubMed ID: 33356992
[TBL] [Abstract][Full Text] [Related]
6. Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes.
Abeykoon JP; Zanwar S; Ansell SM; Gertz MA; Kumar S; Manske M; Novak AJ; King R; Greipp P; Go R; Inwards D; Muchtar E; Habermann T; Witzig TE; Thompson CA; Dingli D; Lacy MQ; Leung N; Dispenzieri A; Gonsalves W; Warsame R; Kyle RA; Rajkumar V; Parikh SA; Kapoor P
Br J Haematol; 2020 Feb; 188(3):394-403. PubMed ID: 31468508
[TBL] [Abstract][Full Text] [Related]
7. Bing-Neel Syndrome: An Initial Manifestation of Waldenstrom Macroglobulinemia.
Lee MS; Sathe S; Valasapalli S; Grosse Perdekamp M
Cureus; 2021 Nov; 13(11):e19402. PubMed ID: 34926004
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound.
Gustine JN; Meid K; Dubeau T; Severns P; Hunter ZR; Guang Y; Xu L; Treon SP; Castillo JJ
Am J Hematol; 2018 Aug; 93(4):511-517. PubMed ID: 29280186
[TBL] [Abstract][Full Text] [Related]
9. Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study.
Castillo JJ; D'Sa S; Lunn MP; Minnema MC; Tedeschi A; Lansigan F; Palomba ML; Varettoni M; Garcia-Sanz R; Nayak L; Lee EQ; Rinne ML; Norden AD; Ghobrial IM; Treon SP
Br J Haematol; 2016 Mar; 172(5):709-15. PubMed ID: 26686858
[TBL] [Abstract][Full Text] [Related]
10. Standard Dose of Ibrutinib is Effective in the Treatment of Bing-Neel Syndrome.
Plander M; Szendrei T; Vadvári Á; Iványi J
Pathol Oncol Res; 2020 Jan; 26(1):591-592. PubMed ID: 30357751
[No Abstract] [Full Text] [Related]
11. Bing-Neel Syndrome, a Rare Presentation of Waldenström Macroglobulinemia-A Multicenter Report by the Polish Lymphoma Research Group.
Drozd-Sokołowska J; Waszczuk-Gajda A; Witkowska M; Sienkiewicz E; Kopińska A; Kołkowska-Leśniak A; Barankiewicz J; Długosz-Danecka M; Smolewski P; Helbig G; Lech-Marańda E; Jurczak W; Biecek P; Giebel S; Wiktor-Jędrzejczak W; Basak G
J Clin Med; 2022 Jul; 11(15):. PubMed ID: 35956064
[TBL] [Abstract][Full Text] [Related]
12. First-line ibrutinib for Bing-Neel syndrome.
Tallant A; Selig D; Wanko SO; Roswarski J
BMJ Case Rep; 2018 Oct; 2018():. PubMed ID: 30279255
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of ibrutinib as first-line treatment of tumoral Bing-Neel syndrome.
Boudin L; Patient M; Roméo E; Bladé JS; de Jauréguiberry JP
Leuk Lymphoma; 2018 Nov; 59(11):2746-2748. PubMed ID: 29569974
[No Abstract] [Full Text] [Related]
14. Rare case of Bing-Neel syndrome treated successfully with ibrutinib.
Hashmi H; Dhanoa JS; Emmons R
BMJ Case Rep; 2019 Jun; 12(6):. PubMed ID: 31243026
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.
Treon SP; Gustine J; Meid K; Yang G; Xu L; Liu X; Demos M; Kofides A; Tsakmaklis N; Chen JG; Munshi M; Chan G; Dubeau T; Raje N; Yee A; O'Donnell E; Hunter ZR; Castillo JJ
J Clin Oncol; 2018 Sep; 36(27):2755-2761. PubMed ID: 30044692
[TBL] [Abstract][Full Text] [Related]
16. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
Dimopoulos MA; Trotman J; Tedeschi A; Matous JV; Macdonald D; Tam C; Tournilhac O; Ma S; Oriol A; Heffner LT; Shustik C; García-Sanz R; Cornell RF; de Larrea CF; Castillo JJ; Granell M; Kyrtsonis MC; Leblond V; Symeonidis A; Kastritis E; Singh P; Li J; Graef T; Bilotti E; Treon S; Buske C;
Lancet Oncol; 2017 Feb; 18(2):241-250. PubMed ID: 27956157
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of ibrutinib in the treatment of Bing-Neel syndrome.
Cabannes-Hamy A; Lemal R; Goldwirt L; Poulain S; Amorim S; Pérignon R; Berger J; Brice P; De Kerviler E; Bay JO; Sauvageon H; Beldjord K; Mourah S; Tournilhac O; Thieblemont C
Am J Hematol; 2016 Mar; 91(3):E17-9. PubMed ID: 26689870
[No Abstract] [Full Text] [Related]
18. Ibrutinib for the treatment of Waldenström macroglobulinemia.
Chakraborty R; Kapoor P; Ansell SM; Gertz MA
Expert Rev Hematol; 2015 Oct; 8(5):569-79. PubMed ID: 26138997
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
Ali N; Malik F; Jafri SIM; Naglak M; Sundermeyer M; Pickens PV
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S53-S61. PubMed ID: 28760303
[TBL] [Abstract][Full Text] [Related]
20. Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy.
Gustine JN; Sarosiek S; Flynn CA; Meid K; Leventoff C; White T; Guerrera ML; Xu L; Kofides A; Tsakmaklis N; Munshi M; Demos M; Patterson CJ; Liu X; Yang G; Hunter ZR; Branagan AR; Treon SP; Castillo JJ
Haematologica; 2022 May; 107(5):1163-1171. PubMed ID: 34162182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
